ZYUS Life Sciences Corporation announced receipt of the final clinical study report and positive results respecting its Phase 1, first-in-human (?FIH?) Clinical Trial for its lead drug product candidate, Trichomylin® softgels.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.04 CAD | -0.95% | -0.95% | +15.56% |
1st Jan change | Capi. | |
---|---|---|
+15.56% | 53.6M | |
+40.80% | 53.67B | |
+35.79% | 38.86B | |
-8.05% | 38.76B | |
-8.98% | 27.27B | |
+10.69% | 25.91B | |
-16.21% | 20.29B | |
+31.00% | 12.78B | |
+28.51% | 12.18B | |
-1.67% | 11.96B |
- Stock Market
- Equities
- ZYUS Stock
- News ZYUS Life Sciences Corporation
- ZYUS Life Sciences Corporation Announces Positive Phase I Clinical Trial Results for Trichomylin® Softgels